日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up

一项针对复发/难治性多发性骨髓瘤的全人源BCMA CAR-T疗法的I期临床试验,随访时间为5年。

Tuazon, Sherilyn A; Portuguese, Andrew J; Pont, Margot J; Cowan, Andrew J; Cole, Gabriel O; Sather, Blythe D; Song, Xiaoling; Thomas, Sushma; Wood, Brent L; Blake, Michelle; Works, Melissa G; Shadman, Mazyar; Liang, Emily C; Wu, Qian V; Voutsinas, Jenna M; Gooley, Ted A; Turtle, Cameron J; Till, Brian G; Coffey, David G; Maloney, David G; Riddell, Stanley R; Green, Damian J

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.

γ-分泌酶抑制剂可提高BCMA特异性嵌合抗原受体T细胞在多发性骨髓瘤中的疗效

Pont Margot J, Hill Tyler, Cole Gabriel O, Abbott Joe J, Kelliher Jessica, Salter Alexander I, Hudecek Michael, Comstock Melissa L, Rajan Anusha, Patel Bharvin K R, Voutsinas Jenna M, Wu Qian, Liu Lingfeng, Cowan Andrew J, Wood Brent L, Green Damian J, Riddell Stanley R